News Quantified

IMUX – immunic, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Immunic (IMUX) was given a new $2.50 price target by Stifel Nicolaus.

Immunic (IMUX) was downgraded by D. Boral Capital from "buy" to "hold".

Immunic to Participate in Scientific and Medical Conferences in April [TheStreet.com]

Immunic to Participate in Scientific and Medical Conferences in April

Immunic regains compliance with Nasdaq minimum bid price requirement [Seeking Alpha]

-6.4%

BEAT

-2.9%

IN-LINE

Form SCHEDULE 13G IMMUNIC, INC. Filed by: Avidity Partners Management LP

Form 8-K IMMUNIC, INC. For: Apr 14

Form 8-K IMMUNIC, INC. For: Apr 07

Form S-8 IMMUNIC, INC.

Form S-3 IMMUNIC, INC.

Top News Gainers

6/24 Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston 90.9%

4/21 Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients 26.9%

3/25 Immunic (NASDAQ: IMUX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 26.7%

3/16 Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements 24.4%

12/11 Immunic (NASDAQ: IMUX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 22.8%

7/17 Form 8-K IMMUNIC, INC. For: Jul 15 12.0%

7/30 Immunic, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference on August 8 10.7%

6/4 Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2n? Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway 10.2%

4/20 Form 8-K IMMUNIC, INC. For: Apr 17 9.5%

2/1 Immunic (NASDAQ: IMUX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 7.3%

Top News Decliners

3/25 Immunic and Cytosorbents among healthcare gainers; Immutep tops the losers [Seeking Alpha] -25.6%

7/11 Immunic (NASDAQ: IMUX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $40.00 price target on the stock. -20.1%

4/21 Immunic up 16% after hours on potential COVID-19 drug [Seeking Alpha] -16.5%

4/30 Form 4 IMMUNIC, INC. For: Apr 29 Filed by: Whaley Glenn -15.9%

4/22 Form 8-K IMMUNIC, INC. For: Apr 21 -13.8%

9/5 Immunic up 26% after hours on encouraging IMU-838 data [Seeking Alpha] -12.2%

7/16 Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer -12.0%

9/20 Form S-8 IMMUNIC, INC. -11.7%

11/19 Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips -10.0%

1/7 Immunic (NASDAQ: IMUX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -9.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day